AMPH
Price
$28.65
Change
+$0.41 (+1.45%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
1.3B
28 days until earnings call
Intraday BUY SELL Signals
DERM
Price
$8.43
Change
-$0.12 (-1.40%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
284.34M
43 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMPH vs DERM

Header iconAMPH vs DERM Comparison
Open Charts AMPH vs DERMBanner chart's image
Amphastar Pharmaceuticals
Price$28.65
Change+$0.41 (+1.45%)
Volume$2.85K
Capitalization1.3B
Journey Medical
Price$8.43
Change-$0.12 (-1.40%)
Volume$300
Capitalization284.34M
AMPH vs DERM Comparison Chart in %
AMPH
Daily Signal:
Gain/Loss:
DERM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AMPH vs. DERM commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMPH is a StrongBuy and DERM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (AMPH: $28.24 vs. DERM: $8.55)
Brand notoriety: AMPH: Not notable vs. DERM: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMPH: 143% vs. DERM: 40%
Market capitalization -- AMPH: $1.3B vs. DERM: $284.34M
AMPH [@Pharmaceuticals: Generic] is valued at $1.3B. DERM’s [@Pharmaceuticals: Generic] market capitalization is $284.34M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.79B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMPH’s FA Score shows that 0 FA rating(s) are green whileDERM’s FA Score has 0 green FA rating(s).

  • AMPH’s FA Score: 0 green, 5 red.
  • DERM’s FA Score: 0 green, 5 red.
According to our system of comparison, AMPH is a better buy in the long-term than DERM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMPH’s TA Score shows that 5 TA indicator(s) are bullish while DERM’s TA Score has 5 bullish TA indicator(s).

  • AMPH’s TA Score: 5 bullish, 5 bearish.
  • DERM’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both AMPH and DERM are a good buy in the short-term.

Price Growth

AMPH (@Pharmaceuticals: Generic) experienced а +7.58% price change this week, while DERM (@Pharmaceuticals: Generic) price change was -1.95% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.90%. For the same industry, the average monthly price growth was -2.44%, and the average quarterly price growth was +12.84%.

Reported Earning Dates

AMPH is expected to report earnings on Mar 04, 2026.

DERM is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.90% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMPH($1.3B) has a higher market cap than DERM($284M). DERM has higher P/E ratio than AMPH: DERM (39.08) vs AMPH (12.50). DERM YTD gains are higher at: 10.895 vs. AMPH (5.452). AMPH has higher annual earnings (EBITDA): 223M vs. DERM (-685K). AMPH has more cash in the bank: 276M vs. DERM (24.9M). DERM has less debt than AMPH: DERM (25.3M) vs AMPH (657M). AMPH has higher revenues than DERM: AMPH (723M) vs DERM (59.4M).
AMPHDERMAMPH / DERM
Capitalization1.3B284M457%
EBITDA223M-685K-32,555%
Gain YTD5.45210.89550%
P/E Ratio12.5039.0832%
Revenue723M59.4M1,217%
Total Cash276M24.9M1,108%
Total Debt657M25.3M2,597%
FUNDAMENTALS RATINGS
AMPH vs DERM: Fundamental Ratings
AMPH
DERM
OUTLOOK RATING
1..100
7115
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
85100
SMR RATING
1..100
5497
PRICE GROWTH RATING
1..100
5043
P/E GROWTH RATING
1..100
3745
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DERM's Valuation (73) in the Biotechnology industry is in the same range as AMPH (74) in the Pharmaceuticals Other industry. This means that DERM’s stock grew similarly to AMPH’s over the last 12 months.

AMPH's Profit vs Risk Rating (85) in the Pharmaceuticals Other industry is in the same range as DERM (100) in the Biotechnology industry. This means that AMPH’s stock grew similarly to DERM’s over the last 12 months.

AMPH's SMR Rating (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for DERM (97) in the Biotechnology industry. This means that AMPH’s stock grew somewhat faster than DERM’s over the last 12 months.

DERM's Price Growth Rating (43) in the Biotechnology industry is in the same range as AMPH (50) in the Pharmaceuticals Other industry. This means that DERM’s stock grew similarly to AMPH’s over the last 12 months.

AMPH's P/E Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as DERM (45) in the Biotechnology industry. This means that AMPH’s stock grew similarly to DERM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMPHDERM
RSI
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 14 days ago
88%
Declines
ODDS (%)
Bearish Trend 8 days ago
70%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AMPH
Daily Signal:
Gain/Loss:
DERM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HYDTF2.920.08
+2.82%
Hydreight Technologies Inc
GIFOF8.85N/A
N/A
Grifols Sa
DWLAF1.32N/A
N/A
DOWLAIS GROUP PLC
STOHF27.36N/A
N/A
Equinor ASA
VPIM0.65N/A
N/A
Vitality Prime Inc.

AMPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMPH has been loosely correlated with AMRX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AMPH jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMPH
1D Price
Change %
AMPH100%
+1.15%
AMRX - AMPH
44%
Loosely correlated
+0.42%
COLL - AMPH
43%
Loosely correlated
+0.85%
ELAN - AMPH
37%
Loosely correlated
-1.62%
BHC - AMPH
36%
Loosely correlated
-1.04%
ZTS - AMPH
33%
Poorly correlated
-2.02%
More

DERM and

Correlation & Price change

A.I.dvisor indicates that over the last year, DERM has been loosely correlated with ETON. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if DERM jumps, then ETON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DERM
1D Price
Change %
DERM100%
-0.47%
ETON - DERM
37%
Loosely correlated
+1.45%
AMLX - DERM
28%
Poorly correlated
-1.23%
CHRS - DERM
27%
Poorly correlated
+2.30%
ANIP - DERM
25%
Poorly correlated
-0.15%
AMPH - DERM
23%
Poorly correlated
+1.15%
More